Aytu BioPharma, Inc. filed a Form 10-Q with the SEC on November 16, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Net revenue: $14,842 thousand for the three months ended September 30, 2026, up from $13,888 thousand in the same period of the prior year, according to the filing.
  • Loss from operations: $(3,929) thousand for the quarter, compared to a loss of $(1,504) thousand in the prior-year period, the filing disclosed.
  • Total assets: $99,170 thousand as of September 30, 2026, down from $105,007 thousand as of June 30, 2026, per the balance sheet.
  • Accumulated deficit: $(351,668) thousand as of September 30, 2026, compared to $(347,787) thousand as of June 30, 2026, the registrant reported.
  • Shares outstanding: 10,868,208 shares of common stock as of November 9, 2026, according to the filing.
  • Proposed acquisition: The filing references a proposed acquisition of the company by Rosemont Pharmaceuticals Holdings, Inc., including a planned tender offer and subsequent merger, described as the "Transaction."

Aytu BioPharma's September 2026 Quarter: Revenue Growth, Wider Operating Loss

Aytu BioPharma, Inc. (NASDAQ:AYTU), a Delaware-incorporated specialty pharmaceutical company headquartered in Denver, Colorado, filed its quarterly report covering the three months ended September 30, 2026. According to the filing, net revenue rose to $14,842 thousand from $13,888 thousand in the comparable prior-year quarter. Gross profit increased to $9,437 thousand from $9,186 thousand, while cost of goods sold grew to $5,405 thousand from $4,702 thousand over the same period.

The registrant reported total operating expenses of $13,366 thousand for the quarter, up from $10,690 thousand a year earlier. The increase was driven by higher selling and marketing expenses of $6,620 thousand (versus $5,322 thousand), general and administrative expenses of $5,985 thousand (versus $4,924 thousand), and amortization of intangible assets of $761 thousand (versus $444 thousand). The resulting loss from operations widened to $(3,929) thousand from $(1,504) thousand in the prior-year quarter, the company disclosed.

As of September 30, 2026, the balance sheet showed cash and cash equivalents of $25,494 thousand, total current assets of $57,164 thousand, and total stockholders' equity of $31,564 thousand, compared to $35,274 thousand at June 30, 2026. The filing also discloses a proposed acquisition of Aytu BioPharma by Rosemont Pharmaceuticals Holdings, Inc. The forward-looking statements in the filing regarding the proposed Transaction, including anticipated timing and consummation, are the company's own and are subject to its cautionary language regarding risks and uncertainties.

What Was Disclosed

Aytu BioPharma filed its quarterly report for the period ended September 30, 2026, disclosing revenue growth to $14,842 thousand, a wider operating loss of $(3,929) thousand, an accumulated deficit of $(351,668) thousand, and a pending proposed acquisition by Rosemont Pharmaceuticals Holdings, Inc.